Vicore announces first human dosed with novel ATRAG, C106 ...Middle East

First healthy volunteer dosed with C106 in a phase 1 trial C106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore's VP03 program Topline data expected Q1 2023 GOTHENBURG, Sweden, June 16, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a...

Hence then, the article about vicore announces first human dosed with novel atrag c106 was published today ( Thursday 16/06/2022 - 09:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Vicore announces first human dosed with novel ATRAG, C106 )

Also on site :

• From Taylor Swift-Approved Jewelry to Made-to-Order Songs: The Most Unique Mother’s Day Gift Ideas for 2026
• 'NCIS' Star Diona Reasonover Reacts to That Big EDNA Twist: 'She Never Saw the Dark Side' (Exclusive)
• Today's NYT Mini Crossword Answers for April 29 – CNET